Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
Hoffmann-La Roche
Hoffmann-La Roche
AstraZeneca
Thomas Jefferson University
Providence Health & Services
AstraZeneca
Hoffmann-La Roche
Hoffmann-La Roche
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
NRG Oncology
Bristol-Myers Squibb
Incyte Corporation
University of Iowa
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Ferring Ventures Limited
EpicentRx, Inc.
Spanish Lung Cancer Group
National Cancer Institute (NCI)
EMD Serono
Spanish Lung Cancer Group
Merck Sharp & Dohme LLC
Hoffmann-La Roche
SWOG Cancer Research Network
AstraZeneca
EQRx International, Inc.
Spanish Lung Cancer Group
Pfizer
EMD Serono
Wake Forest University Health Sciences
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Bristol-Myers Squibb
Innovent Biologics (Suzhou) Co. Ltd.
Incyte Corporation
Incyte Corporation
Case Comprehensive Cancer Center
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC
Merck KGaA, Darmstadt, Germany
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Bristol-Myers Squibb